Prevention and control of hepatitis B in China
- PMID: 12116043
- DOI: 10.1002/jmv.10094
Prevention and control of hepatitis B in China
Abstract
About 170 million Chinese are infected chronically with HBV and 10% suffer from chronic hepatitis. Around half a million Chinese die from hepatitis B caused hepatocellular carcinoma and endstage cirrhosis each year. From 1983 to the present, a controlled clinical trial involving 80,000 children on a universal hepatitis B vaccination programme to prevent chronic hepatitis, hepatocellular carcinoma, and endstage cirrhosis was implemented in Qidong, China. A pilot study demonstrated that the HBsAg rate reached the adult level before the fifth year of age, and neonatal vaccination with either plasma-derived or recombinant hepatitis B vaccines provided a similar 75% protective efficacy against HBV infection. The high rate of follow-up and blood tests coverage of the cohorts provided data to show 75% protection at the tenth to eleventh years of age against serum HBsAg and also against prolonged hepatic dysfunction. The strategy of controlling hepatitis B nationwide was based on the universal immunisation of newborns, beginning in cities and then the rural areas. The large-scale vaccine source was provided by domestic plants through technology transfer, first providing plasma-derived vaccine replaced completely by recombinant DNA vaccine in 1997. An official survey in 1999 using a cluster sampling of 25,878 children from 31 provinces reported an average coverage rate of three dose of hepatitis B vaccination of 70.7%, being higher in urban areas. The Ministry of Public Health of China has planned to integrate hepatitis B vaccination into the nationwide EPI program with Government-provided vaccines starting January 1, 2002.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
[Long-term efficacy of infant hepatitis B immunization program].Zhonghua Gan Zang Bing Za Zhi. 2003 Apr;11(4):203-5. Zhonghua Gan Zang Bing Za Zhi. 2003. PMID: 12716514 Chinese.
-
Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study.Cancer Detect Prev. 1991;15(4):313-8. Cancer Detect Prev. 1991. PMID: 1665400 Clinical Trial.
-
A pilot study on universal immunization of newborn infants in an area of hepatitis B virus and primary hepatocellular carcinoma prevalence with a low dose of hepatitis B vaccine.J Cell Physiol Suppl. 1986;4:83-90. J Cell Physiol Suppl. 1986. PMID: 3018008
-
The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Vaccine. 2013. PMID: 24331015 Review.
-
Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.Int J Infect Dis. 2012 Feb;16(2):e82-8. doi: 10.1016/j.ijid.2011.10.009. Epub 2011 Dec 17. Int J Infect Dis. 2012. PMID: 22178658 Review.
Cited by
-
Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries.Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):45-55. doi: 10.21037/hbsn-21-75. Epub 2021 Jul 21. Hepatobiliary Surg Nutr. 2023. PMID: 36860251 Free PMC article.
-
Liver cancer mortality over six decades in an epidemic area: what we have learned.PeerJ. 2021 Feb 3;9:e10600. doi: 10.7717/peerj.10600. eCollection 2021. PeerJ. 2021. PMID: 33604165 Free PMC article.
-
Analysis of inpatients' characteristics and spatio-temporal distribution of liver cancer incidence in Wuwei, Gansu Province, from 1995 to 2016: A long-term span retrospective study.Medicine (Baltimore). 2020 Jan;99(4):e18870. doi: 10.1097/MD.0000000000018870. Medicine (Baltimore). 2020. PMID: 31977889 Free PMC article.
-
Liver cancer incidence and mortality in China: Temporal trends and projections to 2030.Chin J Cancer Res. 2018 Dec;30(6):571-579. doi: 10.21147/j.issn.1000-9604.2018.06.01. Chin J Cancer Res. 2018. PMID: 30700925 Free PMC article.
-
Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study.J Cancer. 2017 Aug 22;8(14):2676-2683. doi: 10.7150/jca.19665. eCollection 2017. J Cancer. 2017. PMID: 28928855 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical